Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appointments, Valeo's board now comprises of eight directors, five of whom are independent.
"We are pleased to welcome Tamara and Didier to the Valeo Board of Directors. Their extensive and diverse investment experience brings valuable insight and perspective to our Board at a time when we are experiencing rapid growth", said Richard MacKay, the company's chairman in a statement.
"We look forward to benefiting from their contribution and guidance as Valeo continues to develop as a leading Canadian pharmaceutical company," he added.
The company noted that Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy.
She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK).
Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. He served as vice-president, Life Science & Technology for Investissement Quebec and vice-president Life Sciences at Fonds de solidarité FTQ.
Valeo Pharma is dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec, the company has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization
Contact the author at jon.hopkins@proactiveinvestors.com